SCHEMBL162419

SCHEMBL162419

CN(C)S(=O)(=O)c1c[c]ccc1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
LMNA P02545 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
HTT P42858 2/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
TNF P01375 1/20 0.42
NOD1 Q9Y239 1/20 0.42
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
MAPT P10636 3/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3136165 0.83 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2RAB9ANPC1
SCHEMBL4318540 0.82 VCAM1 (0.40) ALDH1A1LMNASMN1; SMN2HTTRAB9A
SCHEMBL3145948 0.80 LMNA (0.44) ALDH1A1LMNASMN1; SMN2HTTRAB9A
SCHEMBL11721090 0.80 CA12 (0.56) ALDH1A1LMNASMN1; SMN2HTTKMT2A
SCHEMBL3278891 0.79 SMN1; SMN2 (0.54) ALDH1A1LMNASMN1; SMN2HTTRAB9A
SCHEMBL27426674 0.78 ALDH1A1 (0.43) ALDH1A1LMNASMN1; SMN2HTTRAB9A
SCHEMBL28055 0.77 ENPP2 (0.39)
SCHEMBL5923176 0.76 HTR6 (0.48) ALDH1A1LMNASMN1; SMN2HTTRAB9A
Water SCHEMBL28154432 0.76 LMNA (0.64) ALDH1A1LMNASMN1; SMN2HTTRAB9A
SCHEMBL182553 0.74 ALDH1A1 (0.54) ALDH1A1LMNASMN1; SMN2HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4304585-A2 METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE Latigo Biotherapeutics, Inc. (US) 2024-01-17 EP claimed
CN-117062607-A Methyl substituted pyridine and pyridazine compounds, derivatives thereof and methods of use thereof 拉堤果生物医疗股份有限公司 2023-11-14 CN claimed
CN-115536635-A Therapeutically active compounds and methods of use thereof 法国施维雅药厂 2022-12-30 CN claimed
CN-115521264-A Therapeutically active compounds and methods of use thereof 法国施维雅药厂 2022-12-27 CN claimed
WO-2022192487-A2 METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC. (US) 2022-09-15 WO claimed
US-20220227732-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2022-07-21 US claimed
EP-3820866-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 Lieber Institute, Inc. (US) 2021-05-19 EP claimed
CN-112689633-A For inhibiting Nav1.8 pyridine carboxamide Compounds 利伯研究所公司 2021-04-20 CN claimed
US-10772874-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. 2020-09-15 US claimed
EP-3019490-B1 N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS INC (US) 2020-06-03 EP claimed
EP-2183239-A1 SULFONAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2010-05-12 EP claimed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US claimed
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 ASTRAZENECA AB (SE) 2009-05-07 US claimed
WO-2009053737-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-04-30 WO claimed
EP-2045237-A1 Pyrrole compounds as inhibitors of mycrobacteria, synthesis thereof and intermediates thereto Universita'Degli Studi di Roma "La Sapienza" (IT) 2009-04-08 EP claimed
WO-2009040755-A2 PYRROLE COMPOUNDS AS INHIBITORS OF MYCOBACTERIA, SYNTHESIS THEREOF ANS INTERMEDIATES THERETO Università degli Studi di Roma 'La Sapienza' (IT) 2009-04-02 WO claimed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 WO claimed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP claimed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227732-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN1A, SCN2A ALDH1A1 2945/4885LMNA 1580/4885SMN1; SMN2 189/4885
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof HTR5A, NPY5R, GRM5 ALDH1A1 2129/4885LMNA 2912/4885SMN1; SMN2 2423/4885
US-10772874-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 ALDH1A1 994/4885LMNA 923/4885SMN1; SMN2 1001/4885
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 MKI67, CCND3, CCND1 ALDH1A1 802/4885LMNA 2005/4885SMN1; SMN2 2234/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 ALDH1A1 3091/4885LMNA 3427/4885SMN1; SMN2 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.